NanoAssemblr Platform

A Disruptive Technology Enabling Transformative Medicine

NxGen logo copy

Nanoparticle, Liposome, LNP

More About the NanoAssemblr Platform

 

Symposium 2021: Genetic Medicine from Concept to Clinic

 

A series of presentations from industry-leading experts focused on the scaling capabilities of lipid-based genetic medicines and benefits of local manufacturing.

 

 

The event is free to attend, with participants from all over the world.

 

 

Register Here


Discovery

药物发现

The
NanoAssemblr®
Spark

Power to Discover

Microliter Nanomedicine Formulations


Learn More
NanoAssemblr Spark
sample-recovery
Unmatched
Sample Recovery

Advanced microfluidics allows microliter formulation volumes with near complete sample recovery.

Spark_intuitive
Intuitive Operation

Simply pipette starting materials into wells, push a button, and pipette completed formulations out.

rapid-production

Rapid Production

The Spark formulation process requires less than 5 seconds, allowing hundreds of formulations to be made in hours.

robust-process

Robust Process

Electronic control minimizes batch-to-batch and user variability.

spark_integration
Workflow Integration

The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture.

Spark_Scalable

Scalable

Shared microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development.

Preclinical

临床前研究

The
NanoAssemblr®
Ignite™

Power to Advance

Designed with the end in mind.

Designed for the future.

Designed to maximize time



Learn More

NanoAssemblr Ignite (Available October 15, 2019)

Ignite replaces the Benchtop October 15, 2019


outstanding-reproducibility
Outstanding
Reproducibility

Advanced microfluidics in an automated system removes batch-to-batch and user-to-user variability.

intuitive-operation

Intuitive Workflow

Easy setup with touch screen interface, saved recipes and a single-use fluid path that eliminates priming and cleaning enables a streamlined workflow.

Ignite_controlled

Controlled Assembly

Tune particle size with precise control over fluid flow rates

versatile

Versatile

Formulate small molecules, peptides, and nucleic acids into lipid, polymer or hybrid nanoparticles, and more.

speedy

Speedy and Efficient

Formulation runs require less than a minute. Over 50 formulations can be completed in a day for rapid optimization.

scalable

Scalable

Easily scale between 1mL and 20mL formulations on the Ignite™. Optimized formulations can be predictably scaled to advanced preclinical and clinical scale with Blaze™ and GMP Systems with NxGen technology.

The
NanoAssemblr®
Blaze

Power to Scale

A direct path to the clinic

Scaling up your genetic medicine



Learn More

NanoAssemblr Blaze

NxGen Blaze Scalable Power

The Scalable Power of NxGen

Efficient formulation for large preclinical studies, with single-mixer flow rate up to 115 mL/min with NxGen technology.

Untitled-2

Direct path to clinic

De-risk processes by using the same NxGen microfluidic mixer on Blaze and GMP.

Blaze_range

high range
of formulation

Formulation of 10 mL to 1L batches with the Blaze or up to 10L with the Blaze+.

Untitled-4

Expanded Process
Development Capabilities

Optional integration to up- and downstream processes and continuous pressure monitoring.

Untitled-3

Validation
of inline dilution

Validation of Inline Dilution.

Blaze_simplicity

Intuitive and easy

The signature simplicity and efficiency of the NanoAssemblr platform.

Manufacturing

制备

GMP System

Power to Commercialize

 

 

Learn More

 

 

The NanoAssemblr GMP System is a modular and configurable system, fit-for-purpose and phase appropriate for the GMP manufacturing of genetic medicine.


The GMP system is a continuous flow microfluidic platform designed for scale up manufacturing of nanoparticles under cGMP conditions. The formulation results are in sync with NanoAssemblr Ignite and Blaze-generated particles.


GMP System
NxGen logo copy
The Evolution of NxGen Technology
The proprietary NxGen microfluidic mixer at the heart of NanoAssemblr systems is designed exclusively for nanomedicine development. NxGen is the only technology that can scale from mL/min to L/h with the same mixer design. NxGen enables time-invariant particle formation to ensure the most reproducible results for a wide range of particle types and is capable of > 25x throughput of our Classic (formerly know as SHM) mixer.
The Evolution of NxGen
From Bench to Commercial Scale

The NxGen mixer uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales.

 

Non-turbulent Mixing

This differs from turbulent mixing where collisions are used to speed mixing. These are extremely dependent on geometric and velocity profiles which differ at scale.



What is Nanomedicine?
Nanomedicines represent the next paradigm in drug innovation, and current research has demonstrated improved efficacy, reduced side effects and revolutionary new treatment modalities like gene therapy and targeted medicine.
Polymeric Nanoparticle

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020

Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019

Vaccines

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerate...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith...

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多
Resource Center 资源中心